Below are the most recent publications written about "Receptors, Calcitonin Gene-Related Peptide" by people in Profiles.
-
Chhabra N, Mead-Harvey C, Dodoo CA, Iser C, Taylor H, Chaudhary H, Vanood A, Dodick DW. Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience. Headache. 2024 Mar; 64(3):233-242.
-
Ashina M, Hoffmann J, Ashina H, Hay DL, Flores-Montanez Y, Do TP, De Icco R, Dodick DW. Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. Mayo Clin Proc. 2024 Feb; 99(2):285-299.
-
George N, Tepper SJ. Novel Migraine Treatments: A Review. J Oral Facial Pain Headache. 2023 Winter; 37(1):27-34.
-
Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022 May; 36(3):341-358.
-
Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019 03; 39(3):445-458.
-
Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018 11; 58 Suppl 3:276-290.
-
Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 11; 58 Suppl 3:238-275.
-
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 11 30; 377(22):2113-2122.
-
Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19; 89(12):1237-1243.
-
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun; 16(6):425-434.